Akamis Bio Limited

UK company 06001442, incorporated on 17 November 2006.

Home | Akamis Bio | Tumor Gene Therapy

Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.

Company number

06001442

Incorporated

17 Nov 2006

Companies House status

Active

Company identity

Founded / incorporated

17 November 2006

Company number 06001442

Verify at Companies House

Legal name

AKAMIS BIO LIMITED

Company type

LTD

Region

South East England

Registered address

Unknown

Insolvency history

Corporate ownership

Updated 07 Jul 2026 09:49

Controls 1

Akamis Bio Limited

No active corporate controller recorded.

Company events

Reference milestones and recent Companies House filing stream events.

1 event

17 Nov

2006

Incorporated

Inception

Company registered at Companies House

Public funding

1 award

First funded

2013

Funded years

2013

Age at first award

6 years

Projects

2013 Collaborative R&D Lead participant

OCTAVE - Ovarian Cancer Trial with an Enhanced Group B Oncolytic Adenovirus

1 Feb 2013 to 31 Dec 2016

Awarded

£1,727,687

Total cost £3,455,373

ColoAd1 is a chimeric adenovirus serotype 3/11p, with a number of key characteristics that may make it a suitable oncolytic agent for the potential treatment of metastatic carcinomas. This is a phase I/IIa study designed to determine the safety, toxicity and tolerability of ColoAd1 and the clinical benefit and potential efficacy of ColoAd1 as a single age...

Product types

Collaborative R&D